Myeloproliferative neoplasms (MPNs), encompassing disorders like polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by …

In recent years the evidence is increasing that chronic inflammation may be an important
driving force for clonal evolution and disease progression in the Philadelphia‐negative …

The Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are acquired stem
cell neoplasms, in which a stem cell lesion induces an autonomous proliferative advantage …

The morbidity and mortality of patients with the chronic Philadelphia-negative
myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera, and …

The JAK2 V617F variant constitutes a genetic alteration of higher frequency in BCR/ABL1
negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G˃ T …

Background Optimal anticoagulation management in patients with myeloproliferative
neoplasms (MPN) experiencing splanchnic vein thrombosis (SpVT) requires balancing risks …

Abstract Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET)
are referred to as the classic Philadelphia chromosome (BCR–ABL1)-negative …

Microparticles are small membrane fragments with dimension between 0.1 and 1 μm, which
are released during cell activation or apoptosis, exposing the phospholipid …

Background: Polycythemia is characterized by increased blood viscosity and a chronic
inflammatory state possibly giving rise to excessive thromboembolic events and …

Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts
and on patient's demographic and clinical history. Despite the numerous studies conducted …